AvidiMab®

AvidiMab® Fc engineering facilitates prolonged antibody target occupancy and/or receptor clustering.

The technology has been shown to improve avidity of anti-glycan antibodies, immune agonist antibodies and receptor blocking antibodies.

Enhanced direct cell killing by GlyMab® through increased activity. More avid glycan binding leads to cancer cell death.

AvidiMab® promotes receptor clustering thereby improving immune signalling.

AvidiMab® promotes receptor clustering thereby improving immune signalling.

  • Promotes non-covalent Fc-Fc interactions of target-bound antibodies
  • Facilitates receptor clustering, improved target occupancy, reduces antibody off-rate
  • Increases direct killing of anti-glycan antibodies and improves efficacy of agonist antibodies

Open to licensing enquiries
commercial@scancell.co.uk

Read the latest news

5

View the Pipeline

5

Read the publications

5

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.